Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.
Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.
复制标题
使用贝伐单抗治疗的非小细胞肺癌患者的肿瘤空化。
DOI：
10.1102/1470-7330.2012.0027
复制
发表时间：
2012-06-29
期刊：
影响因子：
--
通讯作者：
Johnson BE
中科院分区：
文献类型：
--
作者：
Nishino M;Cryer SK;Okajima Y;Sholl LM;Hatabu H;Rabin MS;Jackman DM;Johnson BE
理由与目的：探讨贝伐单抗治疗非小细胞肺癌（NSCLC）患者肿瘤空化的频率和影像学表现，并将影像学表现与病理、临床特征和预后联系起来。材料和方法：回顾性分析72例接受贝伐单抗治疗的非小细胞肺癌患者。回顾了基线和随访的胸部计算机断层扫描，以确定肿瘤空化和随后的空化填充。影像学空化表现分为3组。临床和预后数据与空腔形成和模式相关。结果：72例患者中，14例患者在开始贝伐单抗治疗后出现空化（19%；中位时间1.5个月；范围1.0-24.8个月）。肿瘤空化的三种影像学表现：(1)优势肺肿瘤内出现空化（n = 8）；(2)发生非显性空洞结节（n = 3）；(3)伴有相邻间质异常的非显性空洞结节（n = 3）。11例患者（79%）出现后续空化填充（从形成空腔到填充时间，中位3.7个月，范围1.9 ~ 22.7个月）。没有观察到临床特征，包括吸烟史，或发生空化的患者与未发生空化的患者之间的生存率有显著差异。吸烟史在3种影像学空化表现上有显著差异（P = 0.006）。有空腔形成者咯血1例，无空腔形成者咯血4例，两组间差异无统计学意义。结论：在接受贝伐单抗治疗的非小细胞肺癌患者中，肿瘤空化发生率为19%，并表现出3种影像学表现。在大多数情况下，后续的空化填充被注意到。
Rationale and objectives: To investigate the frequency and radiographic patterns of tumoral cavitation in patients with non-small cell lung cancer (NSCLC) treated with bevacizumab, and correlate the imaging findings with the pathology, clinical characteristics and outcome. Materials and methods: Seventy-two patients with NSCLC treated with bevacizumab therapy were identified retrospectively. Baseline and follow-up chest computed tomography scan were reviewed to identify tumoral cavitation and subsequent filling in of cavitation. Radiographic cavitation patterns were classified into 3 groups. The clinical and outcome data were correlated with cavity formation and patterns. Results: Out of 72 patients, 14 patients developed cavitation after the initiation of bevacizumab therapy (19%; median time to event, 1.5 months; range 1.0–24.8 months). Three radiographic patterns of tumoral cavitation were noted: (1) development of cavity within the dominant lung tumor (n = 8); (2) development of non-dominant cavitary nodules (n = 3); and (3) development of non-dominant cavitary nodules with adjacent interstitial abnormalities (n = 3). Eleven patients (79%) demonstrated subsequent filling in of cavitation (the time from the cavity formation to filling in; median 3.7 months; range 1.9–22.7 months). No significant difference was observed in the clinical characteristics, including smoking history, or in the survival between patients who developed cavitation and those who did not. Smoking history demonstrated a significant difference across 3 radiographic cavitation patterns (P = 0.006). Hemoptysis was noted in 1 patient with cavity formation and 4 patients without, with no significant difference between the 2 groups. Conclusion: Tumoral cavitation occurred in 19% in patients with NSCLC treated with bevacizumab and demonstrated 3 radiographic patterns. Subsequent filling in of cavitation was noted in the majority of cases.
登录
查看更多内容
影响因子：
5
作者：
Smith, Andrew Dennis;Lieber, Michael L.;Shah, Shetal N.
通讯作者：
Shah, Shetal N.
影响因子：
45.3
作者：
Choi, Haesun;Charnsangavej, Chuslip;Benjamin, Robert S.
通讯作者：
Benjamin, Robert S.
影响因子：
158.5
作者：
Sandler, Alan;Gray, Robert;Johnson, David H.
通讯作者：
Johnson, David H.
DOI：
10.1158/1078-0432.ccr-09-0520
发表时间：
2009-08-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Horn L;Sandler A
通讯作者：
Sandler A
影响因子：
5.3
作者：
Lee, Ho Yun;Lee, Kyung Soo;Chung, Myung Jin
通讯作者：
Chung, Myung Jin